Revolution Medicines, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter filing; selected unaudited fourth-quarter results are included below. The company is a clinical-stage oncology drug developer with no approved products or product-sales revenue.
Financial results and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Collaboration revenue | $43.0 million | $50.0 million |
| Research and development expense | $132.3 million | $91.8 million |
| General and administrative expense | $21.4 million | $12.4 million |
| Operating loss | $110.7 million | $54.1 million |
| Net loss | $108.2 million | $47.7 million |
| Net loss per share attributable to common stockholders | $2.01 | $22.33 |
| Cash, cash equivalents and marketable securities at year-end | $440.7 million | $122.8 million |
| Working capital at year-end | $406.9 million | $90.9 million |
- All 2020 revenue was collaboration revenue, primarily reimbursements under the Sanofi SHP2 collaboration; there were no product sales. Revenue declined 14% year over year.
- Research and development expense rose 44%, mainly from greater preclinical portfolio spending; general and administrative expense rose 73%, including costs associated with operating as a public company. Operating expenses substantially exceeded revenue.
- Operating cash use was $100.1 million, compared with $49.6 million in 2019. Investing activities used $234.2 million, largely reflecting purchases of marketable securities; financing activities provided $422.8 million, primarily from the IPO and July 2020 follow-on offering.
- Total liabilities were $92.7 million at year-end, including $32.7 million of operating lease liabilities. The filing reports no off-balance-sheet arrangements and does not identify material conventional borrowings.
- The company reported $440.7 million in year-end cash, cash equivalents and marketable securities and said it expected this liquidity to fund planned operations for at least 12 months following the report. A February 2021 follow-on offering generated approximately $281.3 million net, subsequent to year-end.
Material changes and business developments
- Net loss more than doubled from 2019 as R&D and G&A spending increased while collaboration revenue declined.
- The February 2020 IPO and July 2020 follow-on offering generated approximately $250.7 million and $167.8 million in net proceeds, respectively. Preferred stock converted to common stock upon the IPO; year-end stockholders’ equity was $474.7 million, compared with a deficit of $152.6 million in 2019.
- RMC-4630, the company’s SHP2 inhibitor, remained its most advanced candidate, being studied in Phase 1/2 trials as monotherapy and in combinations. The company selected recommended Phase 2 schedules for monotherapy and the cobimetinib combination.
- RMC-5552 received FDA authorization to proceed under an IND, with first patient dosing planned for the first half of 2021. RMC-5845, RMC-6291 and RMC-6236 remained in preclinical development.
Outlook, commentary and risks
- Management expects significant expenses and operating losses to continue for at least several years; the company has never generated product-sales revenue and may never become profitable.
- Management anticipated initiating RMC-5552 dosing in the first half of 2021 and reporting initial safety, pharmacokinetic and activity data in 2022; it planned to submit INDs for RMC-6291 and RMC-6236 in the first half of 2022 and for RMC-5845 in the second half of 2021. These are forward-looking plans, not assured outcomes.
- Sanofi reimburses substantially all approved SHP2 development costs and shares U.S. commercialization profits and losses equally; Revolution Medicines is also eligible for ex-U.S. royalties and potential milestones. Sanofi has significant program control and may terminate the collaboration under specified terms, including for convenience.
- Preliminary RMC-4630 findings included single-agent disease control in some patients and an individual complete response in an NF1-mutant tumor. Combination findings were based on small interim cohorts. The filing cautions that interim results may change and may not predict later-stage outcomes.
- RMC-4630 safety observations included diarrhea, anemia, fatigue, thrombocytopenia and edema; one grade 4 treatment-related thrombocytopenia event was reported in an intermittent-dose cohort. The company also noted overlapping toxicities in the osimertinib combination study.
- COVID-19 could disrupt trial enrollment, site operations, supply and development timelines. Other central risks include clinical and regulatory failure, patient-enrollment challenges, competition, dependence on third-party manufacturers and collaborators, intellectual-property uncertainty, and the need for additional capital.
- The company adopted the new lease-accounting standard in 2020, recognizing operating lease right-of-use assets and liabilities; management reported no impact on the income statement. Management assessed internal control over financial reporting as effective; the auditor did not provide an internal-control attestation because the company qualified as an emerging growth company.
Most important facts for investors to verify
- Whether RMC-4630’s clinical efficacy and tolerability hold up in larger, longer-running trials, and whether combination toxicities affect its use.
- Progress against stated trial, data-readout and IND-submission timelines for RMC-5552, RMC-5845, RMC-6291 and RMC-6236.
- Cash burn, future financing needs and the effect of the February 2021 offering on runway and dilution; distinguish year-end liquidity from post-year-end proceeds.
- Sanofi’s continued funding and development decisions, collaboration economics, and any changes to the agreement or program responsibilities.
- Potential COVID-19, manufacturing, enrollment, regulatory and intellectual-property developments that could delay or impede pipeline advancement.